Physician profile
Adam Mueller
NPI 1639554561
$4,083.17
in general payments reported to CMS, 2019-2025
20 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $116 · 2021: $113 · 2022: $598 · 2023: $918 · 2024: $677 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,945 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,944.97 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $858.74 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Alcon Vision LLC | $735.64 | 2021-2025 | Hydrus Microstent, Voyager Dslt, Clareon |
| Abbvie INC. | $483.98 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $433.07 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $235.29 | 2025 | Xdemvy |
| Coopervision INC. | $200.12 | 2019-2022 | |
| Amgen INC. | $185.80 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $143.75 | 2022-2023 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $134.06 | 2025 | Acthar |
| Dompe US, INC. | $121.83 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $116.48 | 2022 | |
| Aerie Pharmaceuticals, INC. | $116.03 | 2020 | |
| Ocular Therapeutix, INC. | $68.26 | 2023 | Dextenza |
| Ani Pharmaceuticals, INC. | $56.76 | 2023-2025 | Iluvien, Purified Cortrophin Gel |
| Harrow Eye, LLC | $55.75 | 2024-2025 | Vevye, Triesence, Iheezo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $40.07 | 2023 | |
| Sight Sciences, INC. | $35.33 | 2024 | Omni Surgical System |
| Genentech USA, INC. | $21.33 | 2025 | Vabysmo |
| Rayner Intraocular Lenses Limited | $21.30 | 2023 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Biotissue Holdings INC. | $19.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.